Aurinia Pharmaceuticals Inc (FRA:IKAP)
€ 8.542 -0.116 (-1.34%) Market Cap: 1.23 Bil Enterprise Value: 978.48 Mil PE Ratio: 0 PB Ratio: 3.30 GF Score: 81/100

Q4 2020 Aurinia Pharmaceuticals Inc Earnings Call Transcript

Feb 24, 2021 / 09:30PM GMT
Release Date Price: €11.85 (-2.55%)
Operator

Greetings, and welcome to the Aurinia Year-end 2020 Financial Results Conference Call. (Operator Instructions) As a reminder, this conference is recorded.

It's now my pleasure to turn the call over to Glenn Schulman, Senior Vice President, Investor Relations. Please go ahead, sir.

Glenn Schulman
Aurinia Pharmaceuticals Inc. - SVP of Corporate Communications & IR

Thank you, Kevin, and good afternoon, everyone. I'm pleased to welcome you to today's call discussing Aurinia's fourth quarter and year-end financial results. Joining me on the call this afternoon are Peter Greenleaf, President and CEO of Aurinia; Neil Solomons, our Chief Medical Officer; Max Colao, Chief Commercial Officer; and Joe Miller, our Chief Financial Officer.

This afternoon, just after 4:00 p.m., we issued our press release announcing our financial results and recent operational highlights, which is accessible from our website at www.auriniapharma.com. And has been filed on our Form 8-K with the SEC

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot